Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

That said, let's consider three stocks yielding well above 4% that income-oriented investors should consider: Pfizer (NYSE: ...

The company expects to launch more than 20 pivotal late-stage trials this year.

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Pfizer's dividend payout ratio is high, but the company is generated enough free cash flow to cover its dividend. Management remains committed to the dividend program despite Pfizer facing a patent ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...